Venclexta

Venclexta

venetoclax

Manufacturer:

AbbVie

Distributor:

The Glory Medicina
/
DKSH
Concise Prescribing Info
Contents
Venetoclax
Indications/Uses
In combination w/ rituximab for the treatment of adult patients w/ chronic lymphocytic leukaemia (CLL) who have received at least 1 prior therapy. As monotherapy for the treatment of patients w/ CLL w/ 17p deletion who have received at least 1 prior therapy, or patients w/ CLL w/o 17p deletion who have received at least 1 prior therapy & for whom there are no other available treatment options.
Dosage/Direction for Use
Initiate therapy at 20 mg once daily for 7 days, followed by a wkly ramp-up dosing schedule to the recommended daily dose of 400 mg.
Administration
Should be taken with food: Swallow whole, do not break/chew/crush. Take approx at the same time each day.
Contraindications
Concomitant use w/ strong CYP3A4 inhibitors at initiation & during ramp-up phase.
Special Precautions
Assess risk of tumor lysis syndrome (TLS) in all patients. Pre-medicate w/ anti-hyperuricemics & ensure adequate hydration. Neutropenia. Monitor blood counts & for signs of infection. Do not administer live attenuated vaccine prior to, during, or after treatment. Embryo-fetal toxicity.
Adverse Reactions
Neutropenia, diarrhea, nausea, anemia, upper resp tract infection, thrombocytopenia, fatigue.
Drug Interactions
Avoid concomitant use of moderate CYP3A inhibitors, strong or moderate CYP3A inducers, P-gp inhibitors, or narrow therapeutic index P-gp substrates.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XX52 - venetoclax ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Venclexta FC tab 10 mg
Packing/Price
14's
Form
Venclexta FC tab 100 mg
Packing/Price
120's
Form
Venclexta FC tab 50 mg
Packing/Price
7's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in